CA2875342C - Sels de desfesoterodine - Google Patents
Sels de desfesoterodine Download PDFInfo
- Publication number
- CA2875342C CA2875342C CA2875342A CA2875342A CA2875342C CA 2875342 C CA2875342 C CA 2875342C CA 2875342 A CA2875342 A CA 2875342A CA 2875342 A CA2875342 A CA 2875342A CA 2875342 C CA2875342 C CA 2875342C
- Authority
- CA
- Canada
- Prior art keywords
- desfesoterodine
- succinate
- salt
- salts
- solid state
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne des sels de desfésotérodine pratiquement purs, des sels de desfésotérodine, leurs formes à l'état solide et des compositions pharmaceutiques comprenant un ou plusieurs des sels de desfésotérodine et/ou de leurs formes à l'état solide.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659829P | 2012-06-14 | 2012-06-14 | |
| US61/659,829 | 2012-06-14 | ||
| US201361818135P | 2013-05-01 | 2013-05-01 | |
| US61/818,135 | 2013-05-01 | ||
| PCT/US2013/045992 WO2013188829A1 (fr) | 2012-06-14 | 2013-06-14 | Sels de desfésotérodine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2875342A1 CA2875342A1 (fr) | 2013-12-19 |
| CA2875342C true CA2875342C (fr) | 2017-06-13 |
Family
ID=48808499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2875342A Expired - Fee Related CA2875342C (fr) | 2012-06-14 | 2013-06-14 | Sels de desfesoterodine |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9315450B2 (fr) |
| EP (1) | EP2760822B1 (fr) |
| CA (1) | CA2875342C (fr) |
| ES (1) | ES2569201T3 (fr) |
| HR (1) | HRP20160363T1 (fr) |
| PL (1) | PL2760822T3 (fr) |
| WO (1) | WO2013188829A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017137955A1 (fr) * | 2016-02-14 | 2017-08-17 | Celestis Pharmaceuticals Pvt. Ltd. | Nouveau (r) et 3-(2-(allyloxy)-5-méthylphényl)-n,n-diisopropyl-3- phénylpropan-1-amine racémique et son utilisation pour la synthèse de (r) et de 2-(3- (diisopropylamino)-1-phénylpropyl)-4-(hydroxyméthyl)phénol racémique |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9203318D0 (sv) | 1992-11-06 | 1992-11-06 | Kabi Pharmacia Ab | Novel 3,3-diphenylpropylamines, their use and preparation |
| EP0957073A1 (fr) | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Dérivés de 3,3-diphénylpropylamines |
| DE10028443C1 (de) | 2000-06-14 | 2002-05-29 | Sanol Arznei Schwarz Gmbh | Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen |
| ATE480531T1 (de) | 2006-05-24 | 2010-09-15 | Pfizer Ltd | Verfahren zur herstellung von benzopyran-2- olderivaten |
| GB0813762D0 (en) | 2008-07-28 | 2008-09-03 | Moseley Darren C | Slatted wall fixing element |
| PL2416761T3 (pl) | 2009-05-11 | 2015-07-31 | Ratiopharm Gmbh | Desfezoterodyna w postaci soli kwasu winowego |
| WO2011158257A1 (fr) | 2010-06-18 | 2011-12-22 | Panacea Biotec Ltd | Méthode de préparation de fesotérodine et d'intermédiaires |
-
2013
- 2013-06-14 CA CA2875342A patent/CA2875342C/fr not_active Expired - Fee Related
- 2013-06-14 ES ES13739534.9T patent/ES2569201T3/es active Active
- 2013-06-14 WO PCT/US2013/045992 patent/WO2013188829A1/fr not_active Ceased
- 2013-06-14 EP EP13739534.9A patent/EP2760822B1/fr not_active Not-in-force
- 2013-06-14 HR HRP20160363TT patent/HRP20160363T1/hr unknown
- 2013-06-14 US US14/406,649 patent/US9315450B2/en not_active Expired - Fee Related
- 2013-06-14 PL PL13739534.9T patent/PL2760822T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20160363T1 (hr) | 2016-06-17 |
| US9315450B2 (en) | 2016-04-19 |
| ES2569201T3 (es) | 2016-05-09 |
| EP2760822A1 (fr) | 2014-08-06 |
| PL2760822T3 (pl) | 2016-09-30 |
| EP2760822B1 (fr) | 2016-03-23 |
| CA2875342A1 (fr) | 2013-12-19 |
| WO2013188829A1 (fr) | 2013-12-19 |
| US20150152044A1 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2791141B1 (fr) | Sel de mono-tartrate de Tofacitinib | |
| US20150232457A1 (en) | Crystalline forms of afatinib di-maleate | |
| EP2603503B1 (fr) | Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation | |
| EP4428129A1 (fr) | Dérivé d'acide phénylpropionique substitué et son utilisation | |
| US9221815B2 (en) | Solid state form of vemurafenib choline salt | |
| WO2023104920A1 (fr) | Solvate d'acétone cristallin de la révéfénacine | |
| CA2875342C (fr) | Sels de desfesoterodine | |
| WO2009124906A2 (fr) | Procédé de préparation de monohydrate d’argatroban | |
| US20030220389A1 (en) | O-substituted 6-methyltramadol derivatives | |
| KR20190005904A (ko) | 3-[2-부틸-1-(2-디에틸아미노-에틸)-1h-벤조이미다졸-5-일]-n-하이드록시-아크릴아미드의 다형체 형태 및 그의 용도 | |
| WO2011072383A1 (fr) | Procédés de purification du lubiprostone | |
| US20250361226A1 (en) | Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt | |
| WO2013181251A1 (fr) | Sel de chlorhydrate de crizotinib sous forme cristalline | |
| JP2023548185A (ja) | クラゾセンタン二ナトリウム塩の安定な結晶性水和物 | |
| US20120178821A1 (en) | Polymorphic form of toremifene citrate and process for its preparation | |
| CN101528667A (zh) | 分离得到的o-脱甲基文拉法辛的羟基和n-氧化物代谢物和衍生物以及治疗方法 | |
| EP2739610B1 (fr) | Procédé de fabrication de l'ivabradine et de ses intermédiaires de synthèse | |
| EP4073047B1 (fr) | Procédé de préparation d'un dérivé d'isoindolinone, nouveaux intermédiaires utilisés pour le procédé et procédé de préparation des intermédiaires | |
| KR101098031B1 (ko) | 암로디핀 니코티네이트의 신규 결정형 및 이의 제조방법 | |
| KR20260003013A (ko) | 5-{2-[벤질-(1-(4-하이드록시페닐)-1-메틸에틸)아미노]-1-하이드록시에틸}벤젠-1,3-디올헤미푸마레이트의 제조 방법 | |
| CN121548563A (zh) | 3-(2,3-二氟苯氧基)氮杂环丁烷的药学上可接受的盐及其用途 | |
| NZ519130A (en) | Ethers of O-desmethyl venlafaxine useful for treating central nervous system disorders | |
| EP3558948A1 (fr) | Nouveau sel d'ivabradine et utilisations de ce dernier | |
| CA3246705A1 (fr) | Intermédiaires utiles pour la préparation d'un analogue de lpxc, et leurs procédés de préparation | |
| CN108530375A (zh) | 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150330 |
|
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |